7Suppliers
12Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Century Therapeutics, Inc. (IPSC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships
2Distinct source URLs
9High confidence
0.779Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Century Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
FCDI FCDI 92% On March 23, 2021, we entered into a Manufacturing and Supply Agreement with FCDI, or, as amended, the Manufacturing Agreement, pursuant to which FCDI will provide certain agreed upon technology tran…
FUJIFILM-CELLULAR-DYNAMICS-INC FUJIFILM-CELLULAR-DYNAMICS-INC 92% FCDI provides certain services to the Company to develop and manufacture iPSCs and immune cells derived therefrom
ARTV Artiva Biotherapeutics, Inc. 72% Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or …
CELU Celularity Inc. 72% Reciprocal relationship from CELU graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the pla…
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE g…
GDTC CytoMed Therapeutics Limited 72% Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC g…
INAB IN8bio, Inc. 72% Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…

Century Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
BMY Bristol-Myers Squibb Company 90% the sublicenses under the FCDI Agreements pursuant to our former Research Collaboration and License Agreement with Bristol-Myers Squibb dated January 7, 2022, or the Collaboration Agreement
BMY Bristol-Myers Squibb Company 90% Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY grap…
FCDI FCDI 90% Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, we paid to FCDI (i) an upfront payment of $10.0 million, and will pay (ii) a percentage of any milestone payme…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from IPSC graph: milestone payments upon the achie…
BMYMP Bristol-Myers Squibb Co 72% milestone payments upon the achievement of certain development and regulatory milestones up to an aggregate of $16.2 million or $12.15 million depending on the product. We additionally agreed to pay …
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely…
GDTC CytoMed Therapeutics Limited 72% Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC g…
INAB IN8bio, Inc. 72% Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…
TCRX TScan Therapeutics, Inc. 72% Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel…
COMPANY-LLC COMPANY-LLC 62% or iPSC-derived allogeneic, cell therapy platforms; ● advance CNTY-813 and CNTY-308 through IND-enabling studies, submit IND applications and, if cleared, initiate and conduct clinical trials; ● cont…
FUJIFILM-CELLULAR-DYNAMICS-INC FUJIFILM-CELLULAR-DYNAMICS-INC 62% hospital processes are just beginning to be familiar and comfortable with their use. As a result, the execution and speed of enrollment of clinical trials in these novel and competitive areas are dif…
RHEINCELL-THERAPEUTICS-GMBH RHEINCELL-THERAPEUTICS-GMBH 62% hospital processes are just beginning to be familiar and comfortable with their use. As a result, the execution and speed of enrollment of clinical trials in these novel and competitive areas are dif…

Century Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IPSC-DEBT-10343 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
IPSC-DEBT-10342 Warrants outstanding: 16112 90% xbrl warrant detail from xbrl 2021-12-31.
IPSC-DEBT Debt stack $3.7M 90% Market cache reports total debt of $3.7M.

Century Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Century Therapeutics, Inc..

Century Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
IPSC-OWNER-RA-CAPITAL-MANAGEMENT-L-P RA CAPITAL MANAGEMENT, L.P. 90% 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 75 tracked holders.

Century Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CRSP CRISPR Therapeutics AG 100.00 2
ARTV Artiva Biotherapeutics, Inc. 100.00 1 ['supplier']
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
TLSA Tiziana Life Sciences Ltd 100.00 2
ACET Adicet Bio, Inc. 100.00 2
CRBU Caribou Biosciences, Inc. 100.00 2
DTIL Precision BioSciences, Inc. 100.00 2
AUTL Autolus Therapeutics plc 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
BEAM Beam Therapeutics Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
ATRA Atara Biotherapeutics, Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
FATE Fate Therapeutics, Inc. 100.00 2 ['customer', 'supplier']
SDGR Schrödinger, Inc. 100.00 2
CLLS Cellectis S.A. 100.00 2
🔐
IPSC
Unlock IPSC Supply Chain Data
Verified relationships include:
FCDIFCDISupplier92%
FUJIFILM-CELLULAR-DYNAMICS-INCFUJIFILM-CELLULAR-DYNAMICS-INCSupplier92%
BMYBristol-Myers Squibb CompanyCustomer90%
BMYBristol-Myers Squibb CompanyCustomer90%
+19 more relationships locked
Subscribe — View plans →